Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine

Microbes and Infection

Volumn 11, Issue 1, 2009, Pages 83-91

  Silva Flannery, Luciana M ^a   Cabrera Mora, Monica ^a   Jiang, Jianlin ^a   Moreno, Alberto ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Malaria; Recombinant chimera; Synthetic peptide; Vaccine

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 4; MALARIA VACCINE; RECOMBINANT LINEAR PEPTIDE CHIMERA; SYNTHETIC LINEAR PEPTIDE CHIMERA; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOGENICITY; MALARIA; MALARIA CONTROL; MOUSE; NONHUMAN; PLASMODIUM YOELII; PRIORITY JOURNAL; SPLEEN CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; BASE SEQUENCE; ERYTHROCYTES; FEMALE; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDES; PLASMODIUM YOELII; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

MUS; PLASMODIUM YOELII; RODENTIA;

EID: 58249097168     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2008.10.009     Document Type: Article

References (30)

1. Snow R.W., Guerra C.A., Noor A.M., Myint H.Y., and Hay S.I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434 (2005) 214-217
2. Kuehn B.M. "Roadmap" aids malaria vaccine efforts. J. Am. Med. Assoc. 298 (2007) 849-851
3. Mu J., Awadalla P., Duan J., McGee K.M., Keebler J., Seydel K., McVean G.A.T., and Su X.-Z. Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nat. Genet. 39 (2007) 126-130
4. Kooij T.W.A., Janse C.J., and Waters A.P. Plasmodium post-genomics: better the bug you know?. Nat. Rev. Microbiol. 4 (2006) 344-357
5. Purcell A.W., Zeng W., Mifsud N.A., Ely L.K., Macdonald W.A., and Jackson D.C. Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design. J. Pept. Sci. 9 (2003) 255-281
6. Bijker M.S., Melief C.J., Offringa R., and van der Burg S.H. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev. Vaccines 6 (2007) 591-603
7. Caro-Aguilar I., Rodriguez A., Calvo-Calle J.M., Guzman F., De la Vega P., Patarroyo M.E., Galinski M.R., and Moreno A. Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens. Infect. Immun 70 (2002) 3479-3492
8. Caro-Aguilar I., Lapp S., Pohl J., Galinski M.R., and Moreno A. Chimeric epitopes delivered by polymeric synthetic linear peptides induce protective immunity to malaria. Microbes Infect 7 (2005) 1324-1337
9. Moreno A., Clavijo P., Edelman R., Davis J., Sztein M., Herrington D., and Nardin E. Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein. Int. Immunol 3 (1991) 997-1003
10. Romero P., Maryanski J.L., Cordey A.S., Corradin G., Nussenzweig R.S., and Zavala F. Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. Immunol. Lett. 25 (1990) 27-31
11. Bergmann C.C., Yao Q., Ho C.K., and Buckwold S.L. Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. J. Immunol 157 (1996) 3242-3249
12. Livingston B.D., Newman M., Crimi C., McKinney D., Chesnut R., and Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19 (2001) 4652-4660
13. Nardin E.H., Nussenzweig V., Nussenzweig R.S., Collins W.E., Harinasuta K.T., Tapchaisri P., and Chomcharn Y. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J. Exp. Med 156 (1982) 20-30
14. Kumar K.A., Oliveira G.A., Edelman R., Nardin E., and Nussenzweig V. Quantitative Plasmodium sporozoite neutralization assay (TSNA). J. Immunol. Methods 292 (2004) 157-164
15. Zwaveling S., Mota S.C.F., Nouta J., Johnson M., Lipford G.B., Offringa R., van der Burg S.H., and Melief C.J.M. Established human papillomavirus Type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol 169 (2002) 350-358
16. Rose K., Zeng W., Brown L.E., and Jackson D.C. A synthetic peptide-based polyoxime vaccine construct of high purity and activity. Mol. Immunol 32 (1995) 1031-1037
17. Tam J.P., Yu Q., and Miao Z. Orthogonal ligation strategies for peptide and protein. Biopolymers 51 (1999) 311-332
18. Tam J.P. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. USA 85 (1988) 5409-5413
19. Lu Y.A., Clavijo P., Galantino M., Shen Z.Y., Liu W., and Tam J.P. Chemically unambiguous peptide immunogen: preparation, orientation and antigenicity of purified peptide conjugated to the multiple antigen peptide system. Mol. Immunol 28 (1991) 623-630
20. Fitzmaurice C.J., Brown L.E., Kronin V., and Jackson D.C. The geometry of synthetic peptide-based immunogens affects the efficiency of T cell stimulation by professional antigen-presenting cells. Int. Immunol 12 (2000) 527-535
21. Patarroyo M.E., Amador R., Clavijo P., Moreno A., Guzman F., Romero P., Tascon R., Franco A., Murillo L.A., and Ponton G. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332 (1988) 158-161
22. Jackson D.C., O'Brien-Simpson N., Ede N.J., and Brown L.E. Free radical induced polymerization of synthetic peptides into polymeric immunogens. Vaccine 15 (1997) 1697-1705
23. Barington T., Skettrup M., Juul L., and Heilmann C. Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infect. Immun 61 (1993) 432-438
24. Ben-Yedidia T., and Arnon R. Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Immunol. Lett. 64 (1998) 9-15
25. Joshi M.B., Gam A.A., Boykins R.A., Kumar S., Sacci J., Hoffman S.L., Nakhasi H., and Kenney R.T. Immunogenicity of well-characterized synthetic Plasmodium falciparum Multiple Antigen Peptide conjugates. Infect. Immun 69 (2001) 4884-4890
26. Shi Y.P., Hasnain S.E., Sacci J.B., Holloway B.P., Fujioka H., Kumar N., Wohlhueter R., Hoffman S.L., Collins W.E., and Lal A.A. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc. Natl. Acad. Sci. USA 96 (1999) 1615-1620
27. Shi Y.P., Das P., Holloway B., Udhayakumar V., Tongren J.E., Candal F., Biswas S., Ahmad R., Hasnain S.E., and Lal A.A. Development, expression, and murine testing of a multistage Plasmodium falciparum malaria vaccine candidate. Vaccine 18 (2000) 2902-2914
28. Zhou Z., Todd C.W., Wohlhueter R.M., Price A., Xiao L., Schnake P., Bonner P.C., Martin A.M., Goldman I.F., De La Vega P., Udhayakumar V., and Lal A.A. Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli. Hum. Vaccin 2 (2006) 14-23
29. Livingston B., Crimi C., Newman M., Higashimoto Y., Appella E., Sidney J., and Sette A. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J. Immunol 168 (2002) 5499-5506
30. Hutchings C.L., Birkett A.J., Moore A.C., and Hill A.V.S. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect. Immun 75 (2007) 5819-5826